Table 1.
Baseline characteristics of the patients with JIA in each CTP group*
|
Overall (n = 400) |
Step‐up CTP (n = 257) |
Early combination CTP (n = 100) |
Biologic first CTP (n = 43) |
P | |
|---|---|---|---|---|---|
| Age, mean ± SD years | 10.40 ± 4.94 | 10.03 ± 5.03 | 11.12 ± 4.54 | 10.89 ± 5.17 | 0.139 |
| Sex, no. (%) male | 106 (26.5) | 65 (25.3) | 25 (25.0) | 16 (37.2) | 0.242 |
| Race, no. (%) | 0.347 | ||||
| Black | 30 (7.5) | 17 (6.6) | 7 (7.0) | 6 (14.0) | |
| Other | 79 (19.8) | 47 (18.3) | 24 (24.0) | 8 (18.6) | |
| White | 291 (72.8) | 193 (75.1) | 69 (69.0) | 29 (67.4) | |
| Time since symptom onset, median (IQR) months | 6.10 (2.90–16.11) | 5.60 (2.76–14.09) | 7.31 (3.51–17.16) | 5.16 (2.10–30.93) | 0.420 |
| Time since diagnosis, median (IQR) months | 0.00 (0.00–0.83) | 0.00 (0.00–0.80) | 0.00 (0.00–0.47) | 0.47 (0.00–2.12) | 0.034 |
| Disease course, no. (%) | 0.001 | ||||
| Enthesitis related | 33 (8.2) | 15 (5.8) | 10 (10.0) | 8 (18.6) | |
| Extended oligoarticular | 14 (3.5) | 12 (4.7) | 0 (0.0) | 2 (4.7) | |
| RF‐negative polyarticular | 242 (60.5) | 171 (66.5) | 54 (54.0) | 17 (39.5) | |
| RF‐positive polyarticular | 78 (19.5) | 42 (16.3) | 28 (28.0) | 8 (18.6) | |
| Psoriatic | 23 (5.8) | 12 (4.7) | 5 (5.0) | 6 (14.0) | |
| Undifferentiated | 10 (2.5) | 5 (1.9) | 3 (3.0) | 2 (4.7) | |
| Previous NSAID use, no. (%)† | 155 (83.3) | 94 (80.3) | 41 (91.1) | 20 (83.3) | 0.257 |
| PGA, mean ± SD (10‐cm VAS)‡ | 5.52 ± 2.12 | 5.07 ± 1.99 | 6.41 ± 2.14 | 6.14 ± 2.02 | <0.001 |
| PtGA, mean ± SD (10‐cm VAS)§ | 4.33 ± 2.68 | 3.94 ± 2.70 | 4.88 ± 2.51 | 5.32 ± 2.51 | 0.001 |
| Clinical JADAS‐10, mean ± SD¶ | 18.08 ± 4.67 | 17.08 ± 4.55 | 20.18 ± 4.37 | 19.05 ± 4.29 | <0.001 |
| No. of joints with active disease, mean ± SD | 12.79 ± 8.58 | 11.89 ± 8.06 | 15.96 ± 9.42 | 10.79 ± 7.86 | <0.001 |
| Duration of morning stiffness, no. (%) | 0.031 | ||||
| None | 64 (16.0) | 50 (19.5) | 7 (7.0) | 7 (16.3) | |
| ≤15 minutes | 43 (10.8) | 29 (11.3) | 7 (7.0) | 7 (16.3) | |
| 16–60 minutes | 123 (30.8) | 73 (28.4) | 33 (33.0) | 17 (39.5) | |
| >60 minutes | 130 (32.5) | 80 (31.1) | 42 (42.0) | 8 (18.6) | |
| Unknown | 40 (10.0) | 25 (9.7) | 11 (11.0) | 4 (9.3) | |
| No. of joints with a limited range of motion, mean ± SD# | 8.89 ± 8.38 | 7.70 ± 7.23 | 12.00 ± 9.92 | 7.91 ± 8.64 | <0.001 |
| Abnormal ESR, no. (%)** | 129 (43.1) | 74 (39.6) | 40 (49.4) | 15 (48.4) | 0.272 |
| Abnormal CRP, no. (%)** | 99 (33.1) | 57 (30.5) | 31 (38.3) | 11 (35.5) | 0.441 |
| C‐HAQ, mean ± SD†† | 0.90 ± 0.72 | 0.80 ± 0.70 | 1.05 ± 0.68 | 1.14 ± 0.85 | 0.002 |
JIA = juvenile idiopathic arthritis; CTP = consensus treatment plan; IQR = interquartile range; RF = rheumatoid factor; NSAID = nonsteroidal antiinflammatory drug; PGA = physician global assessment of disease activity; VAS = visual analog scale; PtGA = patient/parent assessment of overall well‐being; JADAS‐10 = Juvenile Arthritis Disease Activity Score in 10 joints; ESR = erythrocyte sedimentation rate; CRP = C‐reactive protein; C‐HAQ = Childhood Health Assessment Questionnaire.
Data were missing for 214 patients.
Data were missing for 5 patients.
Data were missing for 37 patients.
Data were missing for 40 patients.
Data were missing for 78 patients.
Data were missing for 101 patients.
Data were missing for 36 patients.